Literature DB >> 10764951

New highly specific agonistic peptides for human melanocortin MC(1) receptor.

M Szardenings1, R Muceniece, I Mutule, F Mutulis, J E Wikberg.   

Abstract

A peptide with very high specificity for the human melanocortin MC(1) receptor identified by phage display was used as a lead for the design of new peptides. Two new peptides, MS05 and MS09, were synthesized and found to bind with sub-nanomolar affinities to the MC(1) receptor. Both these peptides showed strong agonistic activity at the MC(1) receptor. The MS05 was the most MC(1) receptor selective as it showed virtually no binding affinity for the MC(4) and MC(5) receptors and only micromolar affinity for the MC(3) receptor. The selectivity and potency of the new peptides make them potent tools for studies of MC(1) receptors, as well as novel potential candidate drugs for the treatment of inflammatory conditions.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10764951     DOI: 10.1016/s0196-9781(99)00207-7

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  9 in total

1.  Melanocortin 1 receptor agonists reduce proteinuria.

Authors:  Annika Lindskog; Kerstin Ebefors; Martin E Johansson; Bergur Stefánsson; Anna Granqvist; Margret Arnadottir; Anna-Lena Berg; Jenny Nyström; Börje Haraldsson
Journal:  J Am Soc Nephrol       Date:  2010-05-27       Impact factor: 10.121

Review 2.  Malignant melanoma and melanocortin 1 receptor.

Authors:  A A Rosenkranz; T A Slastnikova; M O Durymanov; A S Sobolev
Journal:  Biochemistry (Mosc)       Date:  2013-11       Impact factor: 2.487

3.  Subcellular trafficking and transfection efficacy of polyethylenimine-polyethylene glycol polyplex nanoparticles with a ligand to melanocortin receptor-1.

Authors:  Mikhail O Durymanov; Elena A Beletkaia; Alexey V Ulasov; Yuri V Khramtsov; Georgiy A Trusov; Nikita S Rodichenko; Tatiana A Slastnikova; Tatiana V Vinogradova; Natalia Y Uspenskaya; Eugene P Kopantsev; Andrey A Rosenkranz; Eugene D Sverdlov; Alexander S Sobolev
Journal:  J Control Release       Date:  2012-09-01       Impact factor: 9.776

4.  Crucial role of the melanocortin receptor MC1R in experimental colitis.

Authors:  C Maaser; K Kannengiesser; C Specht; A Lügering; T Brzoska; T A Luger; W Domschke; T Kucharzik
Journal:  Gut       Date:  2006-03-16       Impact factor: 23.059

5.  Neuroprotective effects of melanocortins in experimental spinal cord injury. An experimental study in the rat using topical application of compounds with varying affinity to melanocortin receptors.

Authors:  H S Sharma; A Skottner; T Lundstedt; M Flärdh; L Wiklund
Journal:  J Neural Transm (Vienna)       Date:  2006-04       Impact factor: 3.575

6.  MC1R is dispensable for the proteinuria reducing and glomerular protective effect of melanocortin therapy.

Authors:  Yingjin Qiao; Anna-Lena Berg; Pei Wang; Yan Ge; Songxia Quan; Sijie Zhou; Hai Wang; Zhangsuo Liu; Rujun Gong
Journal:  Sci Rep       Date:  2016-06-08       Impact factor: 4.379

7.  The synthetic melanocortin (CKPV)2 exerts anti-fungal and anti-inflammatory effects against Candida albicans vaginitis via inducing macrophage M2 polarization.

Authors:  Hai-xia Ji; Yu-lian Zou; Jing-jing Duan; Zhi-rong Jia; Xian-jing Li; Zhuo Wang; Li Li; Yong-wen Li; Gen-yan Liu; Ming-qing Tong; Xiao-yi Li; Guo-hui Zhang; Xiang-rong Dai; Ling He; Zhi-yu Li; Cong Cao; Yong Yang
Journal:  PLoS One       Date:  2013-02-14       Impact factor: 3.240

8.  Effects of melanocortin 1 receptor agonists in experimental nephropathies.

Authors:  Annika Lindskog Jonsson; Anna Granqvist; Johannes Elvin; Martin E Johansson; Börje Haraldsson; Jenny Nyström
Journal:  PLoS One       Date:  2014-01-30       Impact factor: 3.240

9.  A Novel Cu(II)-Binding Peptide Identified by Phage Display Inhibits Cu2+-Mediated Aβ Aggregation.

Authors:  Xiaoyu Zhang; Xiancheng Zhang; Manli Zhong; Pu Zhao; Chuang Guo; You Li; He Xu; Tao Wang; Huiling Gao
Journal:  Int J Mol Sci       Date:  2021-06-25       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.